221 related articles for article (PubMed ID: 9727758)
1. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen.
Johansen HK; Kovesi TA; Koch C; Corey M; Høiby N; Levison H
Pediatr Pulmonol; 1998 Aug; 26(2):89-96. PubMed ID: 9727758
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia.
Jacques I; Derelle J; Weber M; Vidailhet M
Eur J Pediatr; 1998 May; 157(5):427-31. PubMed ID: 9625343
[TBL] [Abstract][Full Text] [Related]
3. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
[TBL] [Abstract][Full Text] [Related]
4. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995).
Frederiksen B; Koch C; Høiby N
Pediatr Pulmonol; 1999 Sep; 28(3):159-66. PubMed ID: 10495331
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.
Frederiksen B; Koch C; Høiby N
Pediatr Pulmonol; 1997 May; 23(5):330-5. PubMed ID: 9168506
[TBL] [Abstract][Full Text] [Related]
6. The clinical presentations of pulmonary aspergillosis in children with cystic fibrosis - preliminary report.
Walicka-Serzysko K; Sands D
Dev Period Med; 2015; 19(1):66-79. PubMed ID: 26003072
[TBL] [Abstract][Full Text] [Related]
7. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.
Govan JR; Brown AR; Jones AM
Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652
[TBL] [Abstract][Full Text] [Related]
8. The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis.
Ramsay KA; Sandhu H; Geake JB; Ballard E; O'Rourke P; Wainwright CE; Reid DW; Kidd TJ; Bell SC
J Cyst Fibros; 2017 Jan; 16(1):70-77. PubMed ID: 27515017
[TBL] [Abstract][Full Text] [Related]
9. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of pulmonary colonization with Burkholderia cepacia in cystic fibrosis patients. The French Observatoire Burkholderia cepacia Study Group.
Segonds C; Chabanon G; Couetdic G; Michel-Briand Y; Bingen E
Eur J Clin Microbiol Infect Dis; 1996 Oct; 15(10):841-2. PubMed ID: 8950569
[No Abstract] [Full Text] [Related]
11. Can early Burkholderia cepacia complex infection in cystic fibrosis be eradicated with antibiotic therapy?
Horsley A; Webb K; Bright-Thomas R; Govan J; Jones A
Front Cell Infect Microbiol; 2011; 1():18. PubMed ID: 22919584
[TBL] [Abstract][Full Text] [Related]
12. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Treggiari MM; Rosenfeld M; Mayer-Hamblett N; Retsch-Bogart G; Gibson RL; Williams J; Emerson J; Kronmal RA; Ramsey BW;
Contemp Clin Trials; 2009 May; 30(3):256-68. PubMed ID: 19470318
[TBL] [Abstract][Full Text] [Related]
13. Clinical and microbiological profile of chronic Burkholderia cepacia complex infections in a cystic fibrosis reference hospital in Brazil.
da Costa Capizzani CP; Caçador NC; Torres LAGMM; Tonani L; Vandamme P; da Costa Darini AL
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2263-2271. PubMed ID: 28840370
[TBL] [Abstract][Full Text] [Related]
14. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
Banerjee D; Stableforth D
Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
[TBL] [Abstract][Full Text] [Related]
15. Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Van Stormbroek B; Zampoli M; Morrow BM
Pediatr Pulmonol; 2019 Apr; 54(4):393-398. PubMed ID: 30656856
[TBL] [Abstract][Full Text] [Related]
16. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial.
Wainwright CE; Vidmar S; Armstrong DS; Byrnes CA; Carlin JB; Cheney J; Cooper PJ; Grimwood K; Moodie M; Robertson CF; Tiddens HA;
JAMA; 2011 Jul; 306(2):163-71. PubMed ID: 21750293
[TBL] [Abstract][Full Text] [Related]
17. A real world evaluation of the long-term efficacy of strategies to prevent chronic Pseudomonas aeruginosa pulmonary infection in children with cystic fibrosis.
Mostofian F; Alkadri J; Tang K; Thampi N; Radhakrishnan D
Int J Infect Dis; 2019 Aug; 85():92-97. PubMed ID: 31132474
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation.
Horsley A; Jones AM
Cochrane Database Syst Rev; 2012 Oct; 10():CD009529. PubMed ID: 23076960
[TBL] [Abstract][Full Text] [Related]
19. Isolation and treatment of cystic fibrosis patients with lung infections caused by Pseudomonas (Burkholderia) cepacia and multiresistant Pseudomonas aeruginosa.
Høiby N
Neth J Med; 1995 Jun; 46(6):280-7. PubMed ID: 7643943
[TBL] [Abstract][Full Text] [Related]
20. Lack of evidence of nosocomial cross-infection by Burkholderia cepacia among Danish cystic fibrosis patients.
Ryley HC; Ojeniyi B; Høiby N; Weeks J
Eur J Clin Microbiol Infect Dis; 1996 Sep; 15(9):755-8. PubMed ID: 8922580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
